Avalyn Pharma Inc. IPO - What You Need to Know

Thinking about jumping into the Avalyn Pharma IPO? Before you invest, let’s break down what this company does in plain English.

Disclaimer: I am an AI, not a financial advisor. IPOs are risky, so please do your own research or talk to a pro before investing.

1. What does this company actually do?

Avalyn Pharma develops inhaled treatments for severe lung diseases, specifically pulmonary fibrosis. Current treatments for conditions like Idiopathic Pulmonary Fibrosis (IPF) are pills. These pills affect the whole body, often causing side effects like stomach issues that force patients to stop treatment.

Avalyn takes proven drugs and reformulates them for inhalation. Using their specialized nebulizer technology, they deliver medicine directly to the lungs. This targets the disease while minimizing side effects. Their lead candidates include:

• AP01 (inhaled pirfenidone): In Phase 2b/3 trials for IPF.
• AP02 (inhaled nintedanib): In Phase 2 trials for IPF.
• AP03 (inhaled treprostinil): An early-stage program for pulmonary hypertension.

2. How do they make money and are they growing?

Avalyn does not make money yet. They have no product sales and won't until the FDA approves one of their treatments.

The company loses money as it funds expensive clinical trials. In 2025, Avalyn reported a loss of $85.2 million, with an accumulated loss of $353.4 million. Don't look for traditional profit metrics here; instead, track their progress through clinical trial milestones.

3. What are the key details of this IPO?

• Ticker Symbol: "AVLN" on the Nasdaq.
• Price Range: Expected between $16.00 and $18.00 per share.
• Share Count: They are offering 16,666,667 shares. If underwriters exercise their option, they will issue an additional 2,500,000 shares.
• Total Ownership: There will be approximately 41.8 million shares outstanding after the offering.

4. What will they do with the money?

Avalyn expects to raise about $258.7 million. They plan to spend it on:

• Clinical Development: Funding the Phase 2b/3 trial for AP01 and the Phase 2 trial for AP02.
• Research and Development: Advancing the AP03 program and other early-stage projects.
• General Corporate Purposes: Covering daily operations and preparing for future manufacturing.

5. What are the main risks?

• Success Depends on Trials: If their drugs fail to prove safe or effective, the company has no other products to fall back on.
• Cash Burn: This money may not be enough to reach commercialization. They will likely need to raise more cash later, which means issuing more shares and reducing your ownership percentage.
• Less Transparency: As an "emerging growth company," Avalyn provides less financial reporting than larger, established companies.
• Device Dependency: Their drugs and nebulizers are regulated as a single unit. If the FDA finds issues with the nebulizer, it could delay or block the entire drug approval.
• Licensing Risks: Their success depends on an exclusive license for the eRapid® Nebulizer System from PARI Pharma. If they lose this license or PARI fails to supply the devices, Avalyn cannot conduct trials or sell its products.

6. Who's running the company?

The leadership team has deep experience in respiratory and orphan drugs. The company didn't provide much detail about specific management backgrounds in the summary filing, but their track record is tied heavily to the successful navigation of FDA clinical pathways.

Final Thought: Investing in a biotech IPO is high-risk and high-reward. Because Avalyn is a "clinical-stage" company, you aren't buying a business with current profits; you are buying a bet on their future clinical trial results. Only invest money you are truly comfortable losing.